CUTISS granted U.S. patent for automation technology in skin tissue therapy

CUTISS has been granted a new patent in the United States for a core element of its automated platform used to manufacture personalized, bio-engineered human skin grafts.

The patent (US Patent No. 12,286,611), titled “Tissue culture vessel for preparation of compressed hydrogel skin grafts and related methods and systems,” protects a key component of the company’s automated tissue engineering process for denovoSkin™, currently in late-stage clinical development for skin surgery.

This patent supports CUTISS’ broader strategy to industrialize personalized skin tissue therapy through standardization, reproducibility, and scalability. The company’s automation efforts have been commenced in collaboration with CSEM and INNOSUISSE and are now being advanced in collaboration with Tecan (read our partnership announcement here), a global leader in laboratory automation.

The granting of this U.S. patent further strengthens our international intellectual property portfolio in the field of regenerative medicine and tissue bio-engineering.